CCL Products Q1 Review - Weak Base Drives Robust Top Line Growth: IDBI Capital
A worker inspects a handful of coffee beans at a processing plant. (Photographer: Tomas Ayuso/Bloomberg)

CCL Products Q1 Review - Weak Base Drives Robust Top Line Growth: IDBI Capital


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

IDBI Capital Report

CCL Products India Ltd.’s Q1 FY22 result was a mixed bag.

While top-line was higher than our estimate by 9%, its Ebitda was 5% below our forecast.

Net sales increased by 13% YoY to Rs 3,261 million mainly on higher offtake.

Ebitda grew 14.5% YoY to Rs 720 million. However, sharp increase in tax expense (up 35% YoY to Rs 99 million) restricted its net profit growth to 13.9% YoY at Rs 438 million.

CCL Products will guide for FY22 sales growth after it reports its Q2 FY22 result; nevertheless, it expects return ratios to improve in FY22 compared to FY21.

Click on the attachment to read the full report:

IDBI Capital CCL Products Q1FY22 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.